September 24, 2017
Combination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma Patients
Newly diagnosed glioblastoma patients treated with Optune plus temozolomide were able to maintain quality of life for longer compared to those treated with temozolomide alone Data presented today as a late-breaking oral presentation at the American Society for Radiation Oncology’s 2017 Annual Meeting ST. HELIER,… Read More
learn more
September 22, 2017
Novocure Announces Data Presentations at the American Society for Radiation Oncology’s 2017 Annual Meeting
Late-breaking oral presentation to focus on Optune five-year survival and health-related quality of life data ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today four presentations on Tumor Treating Fields (TTFields) at the American Society for Radiation Oncology’s (ASTRO) 2017 Annual Meeting, September 24 through September… Read More
learn more
September 6, 2017
Novocure Announces Data Presentations at the ESMO 2017 Congress
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that four data presentations on Tumor Treating Fields (TTFields) will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress, September 8 through September 12 in Madrid, Spain. Among the highlights is a poster discussion of the overall… Read More
learn more
September 5, 2017
German Federal Joint Committee Announces Decision to Support a Clinical Trial to Study Optune® for the Treatment of Newly Diagnosed Glioblastoma
Proposed trial design will examine the benefit of combining Optune with radiation therapy and temozolomide prior to the initiation of maintenance temozolomide ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that the German Federal Joint Committee, (Gemeinsamer Bundesausschuss or G-BA), has published its decision to support… Read More
learn more
